Amura

About:

Amura is a structure-based drug discovery business specializing in diseases such as osteoporosis, osteoarthritis, malaria, and more.

Website: http://www.amura.co.uk

Top Investors: Avlar BioVentures

Description:

Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a proprietary technology platform (AMcoreâ„¢) that provides a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets. Amura compounds possess highly desirable drug-like properties; thereby facilitating the rapid and innovative discovery of orally active pharmaceutical ingredients across several disease areas. Amura has assembled advanced pre-clinical packages for its programmes demonstrating efficacy in disease-related animal models as well as safety pharmacology profiling. Amura intends to license out the programmes. Amura's research and development activities are based at the Babraham Research Campus, Cambridge, United Kingdom.

Total Funding Amount:

$1.84M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Babraham, Cambridgeshire, United Kingdom

Founded Date:

2002-01-01

Contact Email:

amura(AT)amura.co.uk

Founders:

Number of Employees:

1-10

Last Funding Date:

2005-05-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai